IL160557A0 - Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain - Google Patents
Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brainInfo
- Publication number
- IL160557A0 IL160557A0 IL16055702A IL16055702A IL160557A0 IL 160557 A0 IL160557 A0 IL 160557A0 IL 16055702 A IL16055702 A IL 16055702A IL 16055702 A IL16055702 A IL 16055702A IL 160557 A0 IL160557 A0 IL 160557A0
- Authority
- IL
- Israel
- Prior art keywords
- parkinson
- brain
- compositions
- treatment
- product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0111200A FR2829028B1 (fr) | 2001-08-29 | 2001-08-29 | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
PCT/FR2002/002946 WO2003020314A1 (fr) | 2001-08-29 | 2002-08-28 | Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160557A0 true IL160557A0 (en) | 2004-07-25 |
Family
ID=8866792
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16055702A IL160557A0 (en) | 2001-08-29 | 2002-08-28 | Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain |
IL193325A IL193325A0 (en) | 2001-08-29 | 2008-08-07 | Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL193325A IL193325A0 (en) | 2001-08-29 | 2008-08-07 | Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain |
Country Status (16)
Country | Link |
---|---|
US (2) | US7217705B2 (xx) |
EP (2) | EP1649849A3 (xx) |
JP (2) | JP2005505551A (xx) |
AR (1) | AR036302A1 (xx) |
AT (1) | ATE328609T1 (xx) |
AU (2) | AU2002337277B2 (xx) |
CA (1) | CA2458348A1 (xx) |
CY (1) | CY1105341T1 (xx) |
DE (1) | DE60212148T2 (xx) |
DK (1) | DK1423145T3 (xx) |
ES (1) | ES2263816T3 (xx) |
FR (1) | FR2829028B1 (xx) |
IL (2) | IL160557A0 (xx) |
MX (1) | MXPA04001645A (xx) |
PT (1) | PT1423145E (xx) |
WO (1) | WO2003020314A1 (xx) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7485732B2 (en) | 2003-06-11 | 2009-02-03 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) * | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
RU2006133258A (ru) * | 2004-02-17 | 2008-04-10 | Лабораториос Дель Др. Эстеве С.А. (Es) | Замещенные азетидиновые производные, их получение и применение в качестве лекарственных средств |
ES2244314B1 (es) * | 2004-02-17 | 2007-02-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos. |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
CA2613235A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
US20070060638A1 (en) * | 2005-08-26 | 2007-03-15 | Olmstead Mary C | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
PT2114933E (pt) | 2007-01-04 | 2011-12-20 | Prosidion Ltd | Agonistas do gpcr de piperidina |
AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
MX2010005925A (es) * | 2007-11-28 | 2010-08-02 | Ucb Pharma Gmbh | Nueva forma polimorfico de rotigotina y proceso para la produccion. |
US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
CN102459240A (zh) | 2009-04-22 | 2012-05-16 | 詹森药业有限公司 | 作为单酰甘油脂肪酶抑制剂的氮杂环丁烷基二酰胺 |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
EA025584B1 (ru) | 2009-12-22 | 2017-01-30 | ЮСиБи ФАРМА ГМБХ | Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина |
US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
RU2013123274A (ru) | 2010-10-22 | 2014-11-27 | Янссен Фармацевтика Нв | Аминопирролидиназетидиндиамиды как ингибиторы моноацилглицеринлипазы |
US9248111B2 (en) * | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
WO2022245900A2 (en) * | 2021-05-21 | 2022-11-24 | Murphy Brian Stuart | Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5635159A (en) * | 1994-08-26 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
FR2783246B1 (fr) * | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
US20030078189A1 (en) * | 1999-12-10 | 2003-04-24 | Yohko Akiyama | Medicinal compositions for oral use |
US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
-
2001
- 2001-08-29 FR FR0111200A patent/FR2829028B1/fr not_active Expired - Fee Related
-
2002
- 2002-08-27 AR ARP020103211A patent/AR036302A1/es not_active Application Discontinuation
- 2002-08-28 WO PCT/FR2002/002946 patent/WO2003020314A1/fr active Application Filing
- 2002-08-28 AT AT02772514T patent/ATE328609T1/de not_active IP Right Cessation
- 2002-08-28 JP JP2003524621A patent/JP2005505551A/ja not_active Ceased
- 2002-08-28 EP EP06000097A patent/EP1649849A3/fr not_active Withdrawn
- 2002-08-28 IL IL16055702A patent/IL160557A0/xx unknown
- 2002-08-28 CA CA002458348A patent/CA2458348A1/en not_active Abandoned
- 2002-08-28 EP EP02772514A patent/EP1423145B1/fr not_active Expired - Lifetime
- 2002-08-28 DK DK02772514T patent/DK1423145T3/da active
- 2002-08-28 ES ES02772514T patent/ES2263816T3/es not_active Expired - Lifetime
- 2002-08-28 AU AU2002337277A patent/AU2002337277B2/en not_active Ceased
- 2002-08-28 PT PT02772514T patent/PT1423145E/pt unknown
- 2002-08-28 MX MXPA04001645A patent/MXPA04001645A/es not_active Application Discontinuation
- 2002-08-28 DE DE60212148T patent/DE60212148T2/de not_active Expired - Lifetime
-
2004
- 2004-02-25 US US10/786,810 patent/US7217705B2/en not_active Expired - Fee Related
-
2006
- 2006-08-31 CY CY20061101241T patent/CY1105341T1/el unknown
-
2007
- 2007-04-04 US US11/696,485 patent/US20070197654A1/en not_active Abandoned
-
2008
- 2008-08-07 IL IL193325A patent/IL193325A0/en unknown
- 2008-09-05 AU AU2008212039A patent/AU2008212039A1/en not_active Abandoned
-
2009
- 2009-12-09 JP JP2009279071A patent/JP2010053153A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2458348A1 (en) | 2003-03-13 |
CY1105341T1 (el) | 2010-03-03 |
US20040209861A1 (en) | 2004-10-21 |
EP1649849A2 (fr) | 2006-04-26 |
US20070197654A1 (en) | 2007-08-23 |
US7217705B2 (en) | 2007-05-15 |
EP1423145A1 (fr) | 2004-06-02 |
PT1423145E (pt) | 2006-09-29 |
ATE328609T1 (de) | 2006-06-15 |
JP2010053153A (ja) | 2010-03-11 |
EP1649849A3 (fr) | 2006-11-02 |
DK1423145T3 (da) | 2006-10-02 |
JP2005505551A (ja) | 2005-02-24 |
AR036302A1 (es) | 2004-08-25 |
MXPA04001645A (es) | 2004-05-31 |
EP1423145B1 (fr) | 2006-06-07 |
WO2003020314A1 (fr) | 2003-03-13 |
IL193325A0 (en) | 2009-02-11 |
AU2002337277B2 (en) | 2008-06-05 |
ES2263816T3 (es) | 2006-12-16 |
AU2008212039A1 (en) | 2008-10-09 |
FR2829028B1 (fr) | 2004-12-17 |
FR2829028A1 (fr) | 2003-03-07 |
DE60212148T2 (de) | 2007-04-19 |
DE60212148D1 (de) | 2006-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL193325A0 (en) | Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain | |
AU2002337277A1 (en) | Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain | |
IL160558A0 (en) | Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain | |
HUP0103654A2 (hu) | Szmilagenin és/vagy anzurogenin-D alkalmazása Alzheimer-kór kezelésére szolgáló gyógyszerkészítmény előállítására | |
TWI340640B (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
HUP0103558A3 (en) | Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury | |
GB0400167D0 (en) | Dopaminergic neurons and proliferation-competent orecursor cells for treating parkinson's disease | |
HUP0302956A3 (en) | Thioflavin derivatives for use in diagnosis of alzheimer's disease, process for preparation of compounds and pharmaceutical compositions containing them | |
SI1303272T1 (sl) | Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni | |
IL188506A0 (en) | Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease | |
HUP0303037A3 (en) | Compounds to treat alzheimer's disease and pharmaceutical compositions containing them | |
AU2003206413A8 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
HUP0402026A3 (en) | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them | |
EP1827468A4 (en) | LEUPROLID ACETATE AND ACETYLCHOLINESTERASE INHIBITORS OR NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
MX9801305A (es) | Composicion de disolucion rapida oral para agonistas de dopamina. | |
IL163102A (en) | Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders | |
HUP0400246A3 (en) | 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use | |
HUP0301167A3 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use | |
IL112895A (en) | Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists | |
HK1046405A1 (zh) | 作為nmda受體拮抗劑用於治療疼痛的取代的1,5-二氫吡咯-2-酮衍生物 | |
HUP0401325A3 (en) | Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds | |
AU2003303141A8 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
IL172213A0 (en) | Compounds useful in the therapy of alzheimer's disease and formulations containing them | |
HUP0301553A3 (en) | Pharmaceutical compositions and their use for treating neurological disorders | |
HUP0102987A3 (en) | Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient |